AdvisorShares Investments LLC Acquires New Stake in DexCom, Inc. $DXCM

AdvisorShares Investments LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, Holdings Channel reports. The fund purchased 7,240 shares of the medical device company’s stock, valued at approximately $481,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Trust Co. of Vermont lifted its position in DexCom by 14.8% during the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after buying an additional 145 shares in the last quarter. CVA Family Office LLC lifted its position in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after buying an additional 147 shares in the last quarter. IFP Advisors Inc lifted its position in DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after buying an additional 178 shares in the last quarter. Personal CFO Solutions LLC lifted its position in DexCom by 5.0% during the 3rd quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock worth $260,000 after buying an additional 185 shares in the last quarter. Finally, Integrated Wealth Concepts LLC lifted its position in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Transactions at DexCom

In other news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the transaction, the director directly owned 25,007 shares in the company, valued at $1,500,670.07. The trade was a 3.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the transaction, the insider owned 382,482 shares in the company, valued at $27,538,704. This represents a 6.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 32,871 shares of company stock worth $2,306,638 in the last ninety days. Insiders own 0.28% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on DXCM. Bank of America cut their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research report on Friday, May 1st. Mizuho set a $75.00 price target on shares of DexCom in a research report on Friday, May 1st. Robert W. Baird set a $80.00 price target on shares of DexCom in a research report on Friday, May 1st. Finally, Benchmark began coverage on shares of DexCom in a research report on Monday, May 11th. They set a “buy” rating and a $77.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $82.42.

DexCom Stock Up 1.9%

DexCom stock opened at $73.74 on Friday. The firm has a market capitalization of $28.45 billion, a PE ratio of 31.51, a P/E/G ratio of 1.22 and a beta of 1.40. The company’s 50-day moving average is $64.17 and its 200-day moving average is $66.44. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. DexCom’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.32 EPS. Sell-side analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.